Jatenzo Cost in Hawaii 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Does Jatenzo Cost in Hawaii in 2026?

The retail cash price for Jatenzo in Hawaii is approximately $900 per month in 2026, consistent with the manufacturer's list price set by Tolmar Pharmaceuticals. That figure applies regardless of which of the three available strengths a patient uses: 158 mg, 237 mg, or 396 mg capsules taken twice daily with a meal. Jatenzo FDA prescribing information confirms the twice-daily-with-food requirement, which influences patient adherence and therefore long-term cost-effectiveness.

Why the Price Is High

Jatenzo is the first oral testosterone approved in the United States that uses a self-emulsifying drug delivery system to achieve systemic absorption through the lymphatic route rather than first-pass hepatic metabolism. That patented delivery system underpins its premium pricing. Swerdloff et al. (J Clin Endocrinol Metab, 2020) reported that in the key Phase 3 trial (N=166), 87% of subjects achieved average serum testosterone concentrations within the normal range (300 to 1,050 ng/dL) during the 12-week maintenance period, validating the formulation's clinical performance.

Price Compared to Other TRT Options in Hawaii

Testosterone cypionate injection (200 mg/mL, generic) typically costs $30 to $60 per month in Hawaii through retail pharmacies. Testosterone gel 1% (generic) runs $60 to $120 per month. Jatenzo at $900 per month is therefore 8 to 15 times more expensive than these alternatives on a cash-pay basis. The FDA's Orange Book listing confirms no generic oral testosterone undecanoate is currently approved in the United States, which keeps the price elevated.

Does Hawaii Medicaid (Med-QUEST) Cover Jatenzo?

Hawaii Medicaid, administered through the Med-QUEST Division, does not cover Jatenzo as of 2026. This aligns with coverage decisions seen in many state Medicaid programs, which have not added Jatenzo to formularies given the availability of lower-cost injectable and topical testosterone products. The Centers for Medicare and Medicaid Services (CMS) national drug policy framework allows states to set their own preferred drug lists, and Hawaii has excluded Jatenzo from Med-QUEST coverage.

What Med-QUEST Does Cover

Hawaii Med-QUEST does cover testosterone cypionate injection and testosterone gel formulations for male hypogonadism when accompanied by appropriate documentation of low serum testosterone and clinical symptoms. Prescribers seeking coverage for these alternatives should reference Endocrine Society Clinical Practice Guidelines (2018) which recommend initiating testosterone therapy when a patient has consistently low morning total testosterone (<300 ng/dL on two separate measurements) combined with signs and symptoms of androgen deficiency.

Prior Authorization for Non-Covered Drugs

Some Hawaii Med-QUEST managed care plans allow a prior authorization exception process for non-formulary drugs when a patient has documented contraindications or intolerances to covered alternatives. In practice, Jatenzo approvals through this route are rare. Patients should ask their prescriber to document any specific reason oral delivery is medically necessary, such as needle phobia with clinical anxiety documentation or a coagulation disorder precluding injection.

Commercial Insurance Coverage for Jatenzo in Hawaii

Coverage varies significantly by plan. Hawaii's major commercial carriers include HMSA (Hawaii Medical Service Association, a Blue Cross Blue Shield affiliate), Kaiser Permanente Hawaii, and UHA Health Insurance. None of these carriers publicly lists Jatenzo as a Tier 1 or Tier 2 formulary drug on their 2026 preferred drug lists, though some may cover it at Tier 3 or non-preferred specialty tier with a prior authorization.

HMSA and Blue Cross Blue Shield Plans

HMSA follows the national BCBS formulary guidance. Jatenzo appears on some BCBS plans at Tier 3 (non-preferred brand), which can mean a copay of $80 to $150 per 30-day supply after the deductible is met. Patients should pull their Summary of Benefits and Coverage (SBC) document and search for "testosterone undecanoate" or the brand name "Jatenzo" to confirm tier placement before filling.

Kaiser Permanente Hawaii

Kaiser Permanente operates an integrated delivery model in Hawaii. Kaiser's drug formulary is managed internally. As of mid-2025, Kaiser Permanente's national formulary does not include Jatenzo as a covered drug, though prescribers within the system may submit a formulary exception request. The FDA drug approval record for Jatenzo (NDA 210234) supports the clinical basis for such a request.

Employer-Sponsored Plans and ACA Marketplace Plans

Employer-sponsored plans that use PBMs such as Express Scripts or CVS Caremark may place Jatenzo on a specialty tier requiring prior authorization. ACA Marketplace plans in Hawaii follow formulary structures set by individual carriers. Patients should call the pharmacy benefits number on their insurance card and ask specifically: "Is NDC 69734-0158-01 (or the applicable NDC for the prescribed strength) covered under my plan, and what tier?"

How Does the Tolmar Savings Card Work for Hawaii Patients?

Tolmar Pharmaceuticals offers a copay assistance program (often called the Jatenzo Savings Card or Patient Savings Program) for commercially insured patients who are not enrolled in a government-funded health program. Hawaii residents with commercial insurance may be eligible.

Eligibility Requirements

To use the Tolmar savings card, a patient must:

• Have a valid commercial insurance plan (Medicaid, Medicare, TRICARE, and other federal or state programs are excluded)
• Be a resident of the United States
• Have a valid Jatenzo prescription from a licensed prescriber

How Much Can Hawaii Patients Save?

Eligible patients may pay as little as $0 per month for Jatenzo under the savings card program, subject to a maximum annual benefit cap. Tolmar has historically set the cap at around $3,000 to $4,800 per year, meaning patients whose commercial plan charges a high specialty copay may exhaust the benefit within 3 to 5 months and then pay full out-of-pocket cost for the remainder of the year. Patients should confirm current program terms directly at Tolmar's official patient support line, as program terms change annually.

Savings Card Does Not Apply to Medicaid

Because Hawaii Medicaid does not cover Jatenzo, the savings card is moot for Med-QUEST enrollees. Those patients must explore alternatives such as compounded oral testosterone undecanoate or covered injectable/topical TRT formulations.

Is Compounded Oral Testosterone Undecanoate Legal in Hawaii?

Yes. Compounded oral testosterone undecanoate is available to Hawaii patients through licensed 503A compounding pharmacies. The FDA's guidance on compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act permits patient-specific compounding by state-licensed pharmacies when a valid prescriber-patient relationship exists and the compound is prepared for an individual patient.

503A vs. 503B: What Hawaii Patients Need to Know

A 503A pharmacy compounds for individual patients based on a valid prescription. A 503B outsourcing facility compounds in bulk and does not require a patient-specific prescription. Testosterone is a Schedule III controlled substance, and testosterone undecanoate specifically is a compound that requires a legitimate clinical indication. Hawaii's Pharmacy and Therapeutics rules align with federal DEA requirements for Schedule III compounding.

Cost of Compounded Oral Testosterone Undecanoate in Hawaii

Compounded oral testosterone undecanoate from a 503A pharmacy can cost as little as $0 per month when covered by certain specialty compounding insurance benefits, or typically $50 to $150 per month on a cash-pay basis, making it substantially cheaper than brand-name Jatenzo at $900 per month. The compound is not FDA-approved and does not carry the same quality assurance standards as Jatenzo, a point the FDA has stated explicitly in its guidance on compounded drug products.

Clinical Equivalence Is Not Guaranteed

Jatenzo uses a proprietary self-emulsifying drug delivery system. Compounded oral testosterone undecanoate formulations vary by pharmacy and may not achieve the same lymphatic absorption profile. Swerdloff et al. (J Clin Endocrinol Metab, 2020) documented that Jatenzo's pharmacokinetic profile produced a mean Cavg testosterone of 421 ng/dL in hypogonadal men during the maintenance phase (N=166), a result tied to the specific lipid-based delivery. Compounded versions have not been tested in equivalent head-to-head pharmacokinetic studies.

Can Hawaii Patients Get Jatenzo via Telehealth?

Yes. Telehealth prescribing of Jatenzo is legal in Hawaii. The state's telehealth parity laws require commercial insurers to cover telehealth visits at parity with in-person visits under Hawaii Revised Statutes Section 431:10A-116.3. A licensed Hawaii prescriber (MD, DO, NP, or PA with prescriptive authority) who establishes a valid patient-provider relationship through a synchronous audio-video telehealth visit may issue a Schedule III controlled substance prescription under DEA regulations, provided the prescriber holds a valid DEA registration for controlled substances.

What a Telehealth Jatenzo Visit Looks Like

A qualifying telehealth evaluation for male hypogonadism typically requires:

• Two fasting morning total testosterone lab draws on separate days showing <300 ng/dL
• Review of signs and symptoms consistent with hypogonadism (per Endocrine Society 2018 guidelines)
• Blood pressure measurement documented before prescribing, given the FDA black-box warning that Jatenzo raises blood pressure
• Confirmation that the patient understands the twice-daily-with-fat-containing-meal dosing requirement

DEA Telehealth Rules for Schedule III Substances

Under the Ryan Haight Online Pharmacy Consumer Protection Act and subsequent DEA rules, prescribing Schedule III controlled substances via telemedicine requires either an in-person evaluation prior to the prescription or qualification under a specific DEA-registered telemedicine exemption. Hawaii providers and telehealth platforms operating in the state must comply with these federal requirements. The DEA telemedicine rules should be reviewed by any clinician before prescribing Jatenzo via a fully remote visit with no prior in-person encounter.

Who Qualifies for Jatenzo in Hawaii? Clinical Criteria

Jatenzo is FDA-approved exclusively for adult males with conditions associated with a deficiency or absence of endogenous testosterone, specifically primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired). The FDA prescribing label states it is not approved for use in males with age-related low testosterone not associated with a structural or genetic cause.

Endocrine Society Diagnostic Thresholds

The Endocrine Society's 2018 Clinical Practice Guideline on Testosterone Therapy in Men with Hypogonadism recommends confirming the diagnosis with two morning total testosterone measurements below 300 ng/dL, combined with signs and symptoms of androgen deficiency. The guideline explicitly states: "We recommend against making a diagnosis of androgen deficiency in men with acute or subacute illness." This standard governs most Hawaii insurance prior authorization requests as well.

Blood Pressure Monitoring Requirement

The FDA added a black-box warning to Jatenzo's label noting that the drug raises blood pressure, which can increase the risk of major adverse cardiovascular events. Prescribers must measure blood pressure before initiating therapy and periodically thereafter. Patients with pre-existing hypertension that is not well-controlled should generally avoid Jatenzo. The American Heart Association 2023 hypertension guidelines define Stage 2 hypertension as systolic 140 mmHg or higher, a level at which Jatenzo is typically contraindicated unless blood pressure is first managed.

Practical Cost-Reduction Strategies for Hawaii Patients

The table below summarizes the main cost pathways for Jatenzo and oral testosterone in Hawaii in 2026, ranked from lowest to highest typical monthly out-of-pocket cost.

| Option | Typical Monthly Cost (Hawaii, 2026) | Covered by Hawaii Medicaid? | Notes | |---|---|---|---| | Compounded oral TU, 503A, cash-pay | $50 to $150 | No | Not FDA-approved; absorption may differ | | Testosterone cypionate injection, generic | $30 to $60 | Yes (with PA) | Requires injection; covered by Med-QUEST | | Jatenzo with Tolmar savings card | $0 to $50 (commercial only) | No | Annual cap applies; expires at cap | | Jatenzo, Tier 3 commercial insurance | $80 to $150 | No | After deductible; varies by plan | | Jatenzo, cash price | ~$900 | No | No discount applied |

Step 1: Verify Insurance Formulary First

Call your insurer's pharmacy benefit line with the Jatenzo NDC numbers (available on FDA's drug database) before filling. Confirm tier, prior authorization requirements, and whether a step-therapy protocol (requiring trial of a cheaper TRT first) applies.

Step 2: Apply for the Tolmar Savings Card Early

The savings card enrollment typically happens at the pharmacy at point of sale or through Tolmar's patient support portal. Processing the card before the first fill avoids paying the full cash price unnecessarily.

Step 3: Ask Your Prescriber About 503A Compounding

If cost remains prohibitive after insurance and savings card, a licensed Hawaii prescriber can write a prescription for compounded oral testosterone undecanoate at a 503A pharmacy. The prescriber should document clinical rationale for oral delivery specifically, which supports the compound's medical necessity framing.

Step 4: Consider Covered Generic Alternatives

For patients whose clinical picture does not specifically require oral administration, testosterone cypionate 200 mg/mL injection every 1 to 2 weeks remains the most cost-effective and Med-QUEST-covered option. The CDC's National Center for Health Statistics data consistently shows injectable testosterone to be the most commonly prescribed TRT formulation in the United States, reflecting both cost and clinical familiarity.

Key Safety Points Hawaii Prescribers and Patients Must Know

Jatenzo's FDA label includes three clinically significant warnings that affect prescribing decisions and monitoring plans.

Blood Pressure Elevation

As noted, Jatenzo raises blood pressure. The FDA prescribing information requires blood pressure measurement prior to initiation and monitoring throughout treatment. In the Phase 3 trial, mean systolic blood pressure increased by approximately 3 to 5 mmHg from baseline.

Polycythemia Risk

Testosterone therapy of any form can raise hematocrit. Jatenzo is no exception. Hematocrit above 54% warrants dose reduction or treatment discontinuation per the label. Baseline complete blood count before initiation and monitoring at 3 to 6 months is standard practice per Endocrine Society guidelines.

Drug Interactions with Antihypertensives

Because Jatenzo can raise blood pressure, concurrent use of antihypertensive medications may require dose adjustment. Hawaii prescribers should document baseline blood pressure and medication list at every Jatenzo initiation visit.